Plain-English translation of NCT06830343 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called designed to help with weight management in adults who are overweight or obese. Researchers will give some participants the medication as either a single injection or multiple injections over time, while others receive a placebo (inactive treatment) to compare results. The main goal is to understand how safe this medication is and how the body processes it.
Current weight management options are limited, and researchers are exploring new treatments to help people safely achieve healthier weights. This trial will provide the first detailed safety information about this medication in humans.
You likely qualify if…
You likely don't qualify if…
You will receive either the medication or a placebo as a subcutaneous injection (under the skin). In the first phase, participants receive a single injection and are monitored. In the second phase, participants receive injections every 4 weeks over a longer period. Throughout the trial, you will have blood tests, physical exams, heart rhythm monitoring, and ultrasounds to make sure the treatment is safe. The study will take several weeks to months depending on which group you join.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Enrollment target
~66 participants
Started
February 2025
Primary completion
August 2026
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Clinical Trials Information Group officer, /
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.